argenex (NASDAQ:ARGX) Price Target Raised to $1,025.00

argenex (NASDAQ:ARGX) had its price objective lifted by Royal Bank Of Canada from $945.00 to $1,025.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other analysts have also weighed in on ARGX. Guggenheim lifted their price objective on argenex from $1,135.00 to $1,185.00 and gave the stock a “buy” rating in a report on Friday. Oppenheimer reduced their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $940.00 price target on shares of argenex in a research note on Thursday, June 25th. Weiss Ratings upgraded shares of argenex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, July 6th. Finally, Morgan Stanley boosted their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,050.50.

argenex Price Performance

ARGX stock opened at $918.22 on Friday. argenex has a twelve month low of $587.37 and a twelve month high of $953.58. The company has a market cap of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45. The business’s 50-day simple moving average is $868.28 and its 200 day simple moving average is $815.22.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, equities research analysts anticipate that argenex will post 26.95 EPS for the current year.

Institutional Investors Weigh In On argenex

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth boosted its stake in argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after buying an additional 73 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares during the period. 60.32% of the stock is currently owned by institutional investors.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.